Immutep Ltd
IMM
Company Profile
Business description
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
Contact
264 George Street
Level 32, Australia Square
SydneyNSW2000
AUST: +61 283157003
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
44
Stocks News & Analysis
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
stocks
Palantir earnings: Blockbuster growth amid high expectations
We raise our fair value estimate off the back of earnings.
stocks
ResMed earnings: Solid showing from ASX healthcare winner
Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,111.10 | 82.30 | 0.91% |
| CAC 40 | 7,635.03 | 13.99 | 0.18% |
| DAX 40 | 23,924.36 | 78.29 | 0.33% |
| Dow JONES (US) | 44,251.91 | 140.17 | 0.32% |
| FTSE 100 | 9,164.31 | 21.58 | 0.24% |
| HKSE | 24,910.63 | 8.10 | 0.03% |
| NASDAQ | 21,182.97 | 266.42 | 1.27% |
| Nikkei 225 | 40,794.86 | 245.32 | 0.60% |
| NZX 50 Index | 12,880.16 | 3.12 | 0.02% |
| S&P 500 | 6,352.27 | 53.08 | 0.84% |
| S&P/ASX 200 | 8,843.70 | 73.30 | 0.84% |
| SSE Composite Index | 3,633.99 | 16.40 | 0.45% |